280 results on '"Thakar, Monica S."'
Search Results
2. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
3. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
4. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.
5. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium
6. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions
7. Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
8. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC
9. MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infection
10. Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells
11. HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide
12. What makes a pediatric or young adult patient an appropriate transplant candidate?
13. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases
14. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
15. Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers
16. The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases
17. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
18. In Vivo Assessment of NK Cell-Mediated Cytotoxicity by Adoptively Transferred Splenocyte Rejection
19. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery
20. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial
21. Supplementary Methods from Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211
22. Data from Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211
23. Revisiting Pre-Transplant Testicular Radiation for Relapse Prophylaxis in Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)
24. Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
25. Revisiting the Role of Post-Transplant Central Nervous System Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
26. Outcomes for Pediatric Myeloid Malignancy Patients Requiring Pediatric Intensive Care Unit (ICU) Admission Post-HCT
27. Egg Size Plasticity in a Seed Beetle: An Adaptive Maternal Effect
28. Clutch Size Manipulations in Two Seed Beetles: Consequences for Progeny Fitness
29. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome
30. IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection
31. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases
32. 116 - Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
33. Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial
34. Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians
35. Outcomes after Hematopoietic Cell Transplant and Gene Therapy for Adenosine Deaminase (ADA) Severe Combined Immune Deficiency: A Combined Analysis from the Primary Immune Deficiency Treatment Consortium (PIDTC) 6901 and 6902 Studies
36. A Primary Immune Deficiency Treatment Consortium (PIDTC) Study of Chronic and Late Onset Medical Complications after Initial Hematopoietic Cell Transplantation (HCT) for Severe Combined Immunodeficiency Disease (SCID)
37. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex–haplo-identical non-myeloablative hematopoietic cell transplantation
38. IQGAP1: Insights into the function of a molecular puppeteer
39. Indications for transplantation in childhood acute leukemia and the impact of minimal residual disease on relapse: a review
40. Case Series
41. Outcomes of Patients Undergoing Third Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies
42. NK Cell Development and Function in Patients with Fanconi Anemia
43. Role of GATA2 in Human NK Cell Development
44. Correction to: Infections in Infants with SCID: Isolation, Infection Screening and Prophylaxis in PIDTC Centers
45. 557 - Revisiting Pre-Transplant Testicular Radiation for Relapse Prophylaxis in Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)
46. 559 - Revisiting the Role of Post-Transplant Central Nervous System Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
47. 169 - Outcomes for Pediatric Myeloid Malignancy Patients Requiring Pediatric Intensive Care Unit (ICU) Admission Post-HCT
48. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers
49. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
50. Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.